Research Information System
Other, pp.9, 2024
RAC-4 SERUM GALECTIN-3 AND S100-B LEVELS IN BIPOLAR
DISORDER: CORRELATION WITH EMOTION REGULATION, FUNCTIONING AND COGNITIVE
FUNCTIONS Oya Coşkun1 , Öznur Aydoğan2 , Suzan Özer3 , Sadiye Visal Buturak4 ,
Ucler Kisa5 , Ercan Tekin5 1 Department of Psychiatry, Midyat State Hospital,
Midyat/Mardin, Turkey 2 Department of Psychiatry, Trabzon Ataköy Psychiatric
and Neurological Diseases Hospital, Çaykara/Trabzon, Turkey 3 Department of
Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey 4
Department of Psychiatry, Mersin University Faculty of Medicine, Mersin, Turkey
5 Department of Biochemistry, Kırıkkale University Faculty of Medicine,
Kırıkkale, Turkey BACKGROUND AND AIM: Bipolar disorder (BD) is a mental illness
that can reduce the quality of life and has been associated with cognitive impairment
even in euthymic periods. The lifetime prevalence of BD has been reported as
0.3 - 1.2%. It is known that there are no available biomarkers in the
identification and management of BD. The immune inflammatory system has been
suggested to be involved in the pathophysiology of BD in recent years and an
increasing number of studies have been conducted in this area. The aim of this
study is to evaluate whether serum levels of Gal-3 and S100-B, which are
inflammatory molecules, can be used as biomarkers in the diagnosis of BD and
the relationship between serum levels of these molecules and emotion
regulation, functionality and cognitive functions. METHODS: The present study,
50 euthymic patients with BD (who applied to the psychiatry outpatient clinic
between October 2021 and January 2022 and were diagnosed with BD according to
the structured clinical interview (SCID-5), according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-V)) and 50 healthy volunteers who
were matched with the patient group in terms of age-sex-education level and who
did not have current or previous psychiatric diagnosis according to SCID-5 were
recruited. The patients were evaluated by using Hamilton Depression Rating
Scale (HAM-D), Young Mania Rating Scale (YMRS), Functioning Assessment Short
Test (FAST), Bipolar Disorder Functioning Questionnaire (BDFQ), Sheehan
Disability Scale (SDS), Emotion Regulation Questionnaire (ERQ), Difficulties in
Emotion Regulation Scale (DERS), Trail Making Test (TMT-A, TMT-B); Functioning
Assessment Short Test (FAST), Emotion Regulation Questionnaire (ERQ),
Difficulties in Emotion Regulation Scale (DERS), Trail Making Test (TMT-A,
TMT-B) were administered to healthy volunteers by the clinical investigator.
Serum Gal-3 and S100-B levels of patients and healthy controls were measured
with the ELISA kit (This study was approved by the ethics committee decision of
Kırıkkale University Clinical Research Ethics Committee, dated 05.10.2021 and
numbered 16/02). RESULTS: In this study, in addition to the fact that Gal-3 and
S100-B levels were found to be higher in BD patients compared to healthy
controls, the hypothesis that inflammatory processes may play a role in the
deterioration of cognitive functions in BD was supported by demonstrating the association
of increased serum Gal-3 level with TMT-B sec, Error TMT-B, TMT A+B, TMT B-A;
and S100-B level with Error TMT-A. The possible role of inflammatory processes
in the deterioration of psychosocial functioning detected by the scales in the
patient group was demonstrated by the positive correlation of serum Gal-3 level
with the FAST-Leisure Activities subscale score and S100-B level with the
BDFQ-Mental Functioning subscale score. CONCLUSIONS: To the best of our
knowledge, this is the first study to examine the level of Gal-3 in BD patients
and to explore the association of Gal-3 and S100-B with emotion regulation,
functionality and cognitive functions in BD patients compared to healthy
controls. These results contribute to growing literature indicating the
inflammatory process in the etiopathogenesis of BD. Larger sample studies with
longitudinal follow-up are needed to clarify the correlation between the
impairment of emotion regulation, functionality, and cognitive functions in BD
and dysregulated inflammatory responses in terms of Gal-3 and S100-B levels.
Moreover, through recent studies showing that Gal-3 and S-100 proteins can be
used as potential therapeutic targets for the treatment of various diseases, it
can be suggested that these biomarkers may be one of the potential new drug
targets that can prevent the progression of cognitive impairment in bipolar
disorder. Keywords: bipolar disorder, cognitive functions, emotion regulation,
functioning, serum Galectin-3, serum S100-B References Boland R, Verduin ML,
Ruiz P (2021) Kaplan & Sadock’s Synopsis of Psychiatry: Lippincott Williams
& Wilkins. Ferrier IN, Stanton BR, Kelly TP et al. (1999)
Neuropsychological function in euthymic patients with bipolar disorder. Br J
Psychiatry. 175: 246-51. Jain A, Mitra P (Updated 2023 Feb 20). Bipolar
Disorder. StatPearls (Internet). Treasure Island (FL): StatPearls Publishing
Copyright © 2024, StatPearls Publishing LLC. https: //www.ncbi.nlm.nih.gov/
books/NBK558998/ Karamustafalıoğlu O (2018) Temel ve Klinik Psikiyatri. Güneş
Tıp Kitabevleri. Trivedi JK (2006) Cognitive deficits in psychiatric disorders:
Current status. Indian J Psychiatry. 48(1): 10-20. Table. Comparison of serum
Gal-3, S100-B and other biochemical parameters in BD and healthy control (HC)
groups. BD BD HC HC p Mean±SD Med. (min-max) Mean±SD Med. (